Lably
Skip to content

Anti-CRISPR

Group of proteins found in phages

  • 12 min read
  • 6 chapters

Related on Lably

Through Bacteria, Genome and Prokaryote

Before the discovery of this type of family proteins, the acquisition of mutations was the only way known that phages could use to avoid CRISPR-Cas mediated shattering, by reducing the binding affinity of the phage and CRISPR. Nonetheless, bacteria have mechanisms to retarget the mutant bacteriophage, a process that it is called "priming adaptation". So, as far as researchers currently know, anti-CRISPR is the most effective way to ensure the survival of phages throughout the infection process of bacteria.

History

Anti-CRISPR systems were first seen in Pseudomonas aeruginosa prophages, which disabled type I-F CRISPR–Cas system, characteristic of some strains of these bacteria. After analysing the genomic sequences of these phages, genes codifying five different Anti-CRISPR proteins (also named Acrs) were discovered. Such proteins were AcrF1, AcrF2, AcrF3, AcrF4 and AcrF5. Research found none of these proteins disrupted the expression of Cas genes nor the assembling of CRISPR molecules, so it was thought that those type I-F proteins directly affected the CRISPR–Cas interference.

Further investigation confirmed this hypothesis with the discovery of 4 other proteins (AcrE1, AcrE2, AcrE3 and AcrE4), which were shown to impede Pseudomonas aeruginosa's CRISPR-Cas system. Furthermore, the locus of the genes codifying these type I-E proteins was really close to the one responsible for the type I-F proteins expression in the same group of phages, leading to the conclusion that both types of proteins worked together. However, these first nine proteins shared no common sequence motifs, which would have made easier the identification of new Anti-CRISPR protein families.

Later on, it was seen that phages that produced such proteins also encoded a putative transcriptional regulator named Aca 1 (anti-CRISPR associated 1) which was genetically located really close to the anti-CRISPR genes. This regulatory protein is supposed to be responsible for the anti-CRISPR gene expression during the infectious cycle of the phage, therefore, both types of proteins (anti-CRISPR and Aca1) seem to work together as a single mechanism.

After some studies, a similar amino-acid sequence to that of Aca1 was found, leading to the discovery of Aca2, a new family of Aca proteins. Aca2 also revealed the existence of five new groups of type I-F anti-CRISPR proteins due to their genomic proximity: AcrF6, AcrF7, AcrF8, AcrF9 and AcrF10. These proteins were not only present in Pseudomonas aeruginosa's phages, as they also affected other cells of the Pseudomonadota (formerly Proteobacteria).

Thanks to the use of bioinformatic tools, in 2016, AcrIIC1, AcrIIC2 and AcrIIC3 protein families were discovered in Neisseria meningitidis (which had been infected by phages previously). Such proteins were the first inhibitors of type II CRISPR–Cas to be found (concretely, they impeded II-C CRISPR–Cas9, the type of mechanism used in the genetic edition of human cells). A year later, a study confirmed the presence of type II-A CRISPR–Cas9 inhibitors (AcrIIA1, AcrIIA2, AcrIIA3 and AcrIIA4) in Listeria monocytogenes (infected by bacteriophages which introduced the anti-CRISPR proteins). Two of those proteins (AcrIIA2 and AcrIIA4) were demonstrated to work properly against Streptococcus pyogenes type II-A defensive CRISPR system.

While the mechanistical bases for many Acrs against other CRISPR systems were well known, only few anti-CRISPRs against the complex III-A CRISPR system had been well characterised before the finding of AcrIIIA2 encoded by Streptococcus thermophilus phage SW3. With the use of bioinformatic tools, phages infecting Streptococcus species were screened with a quilt-by-association method. Adjacent to the gene encoding the previously known anti-CRISPR protein AcrIIA6 against type II-A CRIPSR systems an anti-CRISPR protein AcrIIIA2 against type III-A-Cas was discovered. It blocks the seed region of crRNA and thereby the binding of target RNA by forming a complex with the host bacterium’s enolase enzyme. This blocks all downstream functions of the type III CRISPR: cleavage of target RNA, cleavage of DNA, and cyclic oligoadenylate synthesis.

The result of all this research has been the discovery of 21 different Anti-CRISPR protein families, despite other inhibitors may exist due to the quick mutational process of phages. Thus, more research is needed to unravel the complexity of anti-CRISPR systems.

Sign in to keep reading

5 more chapters are free with a Lably account.

More in Biology